RxDoctor Payments Data

Lisa Behneke, PA

Medical · Lynchburg, VANPI 1801807797

Payments from drug & device makers

$1,404in general payments, 2019–2025

Across 52 payments — averaging $27.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$438
  • Boston Scientific$126
  • Novartis$121
  • Biosense Webster, Inc.$98
  • Abbott$95
  • Boehringer Ingelheim$95
  • plus $431 from 12 others

What the payments were for

  • Food & beverage$1,404100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,404 in reported general payments places this provider in the 65th percentile of 632 medical providers in Virginia.

See all medical providers in Virginia

Medicare billing

Part B allowed, 2024
$157,609
Medicare patients
1,251
Services billed
2,849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban558$692,248
EntrestoSacubitril/Valsartan84$118,694
XareltoRivaroxaban90$118,293
JardianceEmpagliflozin90$104,403
MultaqDronedarone Hcl29$49,262
Repatha SureclickEvolocumab39$46,498
Dofetilide105$24,498
Metoprolol Succinate643$9,033
VascepaIcosapent Ethyl12$8,154
Praluent PenAlirocumab13$6,360
Diltiazem 12hr ErDiltiazem Hcl17$5,900
Dabigatran EtexilateDabigatran Etexilate Mesylate23$5,333
Flecainide Acetate82$4,045
Diltiazem 24hr Er (Cd)Diltiazem Hcl69$3,681
Amiodarone Hcl163$3,541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$82$692,248558 claims
NovartisEntresto$121$118,69484 claims
Johnson & JohnsonXarelto$26$118,29390 claims
Boehringer IngelheimJardiance$95$104,40390 claims
Sanofi-aventis U.S. LLCMultaq$23$49,26229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 632 medical providers in Virginia.

Other medical in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →